Document Detail

Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
MedLine Citation:
PMID:  17622759     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE: It is widely accepted that antiplatelet therapy is effective for secondary prevention of atherosclerotic vascular diseases. We performed a double-blind, controlled clinical-pharmacological study to investigate the antiplatelet efficacy of sarpogrelate, a selective 5-hydroxytryptamine (5-HT(2A)) receptor antagonist, in patients with ischemic stroke, using a new assessment system employing combinations of 5-HT and epinephrine as agonists. METHODS: Forty-seven patients with ischemic stroke were randomly assigned to three groups: 15 patients received 25 mg sarpogrelate (group L), 16 patients received 50 mg (group M), and 15 patients received 100 mg (group H) orally, three times daily for 7 days. The effect was expressed as maximum intensity of platelet aggregation on the last day of medication. Two combinations of agonists, 0.5 micromol/l 5-HT plus 3 micromol/l epinephrine, and 1 micromol/l 5-HT plus 3 micromol/l epinephrine, were used to induce platelet aggregation. RESULTS: With both combinations of agonists, sarpogrelate treatment inhibited platelet aggregation dose-dependently (p < 0.025, Jonckheere test). In multiple-group comparison, the effect in group H was greater than that in group L or M (p < 0.025, Wilcoxon rank-sum test). CONCLUSION: Sarpogrelate treatment inhibited platelet aggregation dose-dependently in patients with ischemic stroke, as judged by a new assessment system employing combinations of 5-HT and epinephrine as agonists.
Shinichiro Uchiyama; Yukio Ozaki; Kaneo Satoh; Kazuoki Kondo; Katsuya Nishimaru
Related Documents :
2946509 - Specific thromboxane synthetase inhibition and haemostasis in insulin-dependent diabetics.
14511849 - The relationship between carotid atherosclerosis and platelet aggregation in elderly.
8344449 - Differential expression of salivary mucin bacterial aggregating activity with caries st...
20050759 - The platelet functions in patients with ankylosing spondylitis: anti-tnf-alpha therapy ...
7074019 - Studies of catalysis by ribonuclease u2. steady-state kinetics for transphosphorylation...
15911179 - Induction of canine pyometra by inoculation of escherichia coli into the uterus and its...
3941029 - Platelet-aggregating activities of metastasizing tumor cells. iv. effects of cell surfa...
12709409 - Cinc-1 is an acute-phase protein induced by focal brain injury causing leukocyte mobili...
8886399 - Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collag...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2007-07-04
Journal Detail:
Title:  Cerebrovascular diseases (Basel, Switzerland)     Volume:  24     ISSN:  1015-9770     ISO Abbreviation:  Cerebrovasc. Dis.     Publication Date:  2007  
Date Detail:
Created Date:  2007-08-23     Completed Date:  2007-10-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9100851     Medline TA:  Cerebrovasc Dis     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  264-70     Citation Subset:  IM    
Department of Neurology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Blood Platelets / drug effects*,  metabolism
Brain Ischemia / blood,  complications*,  drug therapy
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Epinephrine / metabolism
Middle Aged
Platelet Aggregation / drug effects*
Platelet Aggregation Inhibitors / administration & dosage,  adverse effects,  therapeutic use*
Platelet Function Tests / methods
Receptor, Serotonin, 5-HT2A / antagonists & inhibitors*,  metabolism
Serotonin / metabolism
Serotonin Antagonists / administration & dosage,  adverse effects,  therapeutic use*
Stroke / blood,  drug therapy*,  etiology
Succinates / administration & dosage,  adverse effects,  therapeutic use*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 0/Receptor, Serotonin, 5-HT2A; 0/Serotonin Antagonists; 0/Succinates; 50-67-9/Serotonin; 51-43-4/Epinephrine; 86819-20-7/sarpogrelate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of c...
Next Document:  The role of higher-level cognitive function in gait: executive dysfunction contributes to fall risk ...